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Abstract
Background & Aims:	Mucosal-	associated	invariant	T	(MAIT)	cells	are	important	innate	
T	 cells	with	 antimicrobial	 and	 immunoregulatory	 activity,	 recently	 found	 to	 be	 de-
pleted	in	blood	of	patients	with	HIV	and	HCV	mono-	infections.	In	this	study,	we	as-
sessed	 the	 impact	 of	 HIV,	 HCV	 and	 HCV/HIV	 co-	infection	 on	 circulating	 and	
intrahepatic	MAIT-	cells	and	correlations	with	liver	fibrosis.
Methods:	In	this	cross-	sectional	study,	nine	healthy	subjects,	nine	HIV,	20	HCV	and	22	
HCV/HIV	co-	infected	patients	were	included.	Blood	and	liver	fine	needle	aspirate	bi-
opsies	 were	 studied	 using	 flowcytometry	 for	 CD3+CD161+Vα7.2+	 MAIT-	cell	 fre-
quency,	 phenotype	 and	 function	 in	HCV	mono-	infected	 and	HCV/HIV	 co-	infected	
patients	without	or	with	mild	fibrosis	(Metavir-	score	F0-	F1)	or	severe	fibrosis	to	cir-
rhosis	(Metavir-	score	F3-	F4).
Results:	Circulating	MAIT-	cells	were	decreased	in	blood	of	HCV,	HIV	and	HCV/HIV	
patients	with	F0-	F1.	In	HCV/HIV	co-	infected	individuals	with	severe	fibrosis	to	cirrho-
sis,	the	frequency	of	circulating	MAIT-	cells	was	even	further	depleted,	whereas	their	
function	was	comparable	to	HCV/HIV	co-	infected	patients	with	low	or	absent	fibrosis.	
In	contrast,	in	HCV	mono-	infected	patients,	MAIT-	cell	frequencies	were	not	related	to	
fibrosis	severity;	however,	MAIT-	cell	function	was	impaired	in	mono-	infected	patients	
with	more	fibrosis.	More	advanced	liver	fibrosis	in	HCV	or	HCV/HIV-	infected	patients	
was	not	reflected	by	increased	accumulation	of	MAIT-	cells	in	the	affected	liver.
Conclusions:	Severe	liver	fibrosis	is	associated	with	dysfunctional	MAIT-	cells	in	blood	
of	HCV	mono-	infected	patients,	and	 lower	MAIT	frequencies	 in	blood	of	HCV/HIV	
co-	infected	patients,	without	evidence	for	accumulation	in	the	liver.
K E Y W O R D S
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1  | INTRODUCTION
Co-	infection	 with	 the	 hepatitis	 C	 virus	 (HCV)	 affects	 an	 estimated	
number	of	2.3	million	people	living	with	the	human	immunodeficiency	
virus	(HIV)	worldwide,	which	translates	into	a	co-	infection	prevalence	
of	6.2%	overall,	6.4%	in	men	who	have	sex	with	men,	and	82.4%	in	
people	who	inject	drugs.	Moreover,	viral	hepatitis	is	a	leading	and	in-
creasingly	important	cause	of	disability	and	mortality	worldwide,	with	
a	doubling	of	the	quality	adjusted	life	years	lost	because	of	HCV	infec-
tion	between	1990	and	2013.1,2	In	HIV-	infected	patients	not	receiving	
combined	antiretroviral	therapy	(cART),	HCV	co-	infection	accelerates	
the	development	of	liver	fibrosis	compared	to	HCV	mono-	infection,3 
and	increases	the	risk	for	liver-	related	and	non-	liver-	related	causes	of	
death.4	This	progressive	 liver	 fibrosis	 in	HCV/HIV	 infection	may	be	
rescued	by	cART,	especially	when	initiated	early	after	HIV	infection	
before	the	development	of	significant	immunodeficiency.5
Mucosal-	associated	invariant	T	(MAIT)	cells	are	a	group	of	innate-	
like	T	cells	that	play	an	important	role	in	the	antimicrobial	response	to	a	
range	of	bacteria	and	yeast	species.6,7	Recently,	it	has	been	shown	that	
viral	 infections,	 including	HCV	 infection,	 also	 activate	MAIT-	cells	 in	
a	TCR-	independent	fashion	dependent	on	cytokines.8	MAIT-	cells	are	
identified	in	blood	as	CD3+CD161+Vα7.2+	cells,	and	comprise	about	
5%	of	 the	 total	T	 cells	 in	 blood	of	 healthy	 individuals.9,10	 Similar	 to	
NK-	cells,	MAIT-	cells	can	be	activated	by	interleukin	(IL)-	12	and	IL-	1811 
to	produce	high	levels	of	IFN-	gamma	and	the	cytotoxic	enzyme	gran-
zyme-	B,	but	also	by	 interaction	of	 the	semi-	invariant	T-	cell	 receptor	
(TCR)	Vα7.2	with	the	non-	polymorphic,	major	histocompatibility	com-
plex	class	I-	related	protein	1	(MR1)	on	antigen	presenting	cells.6,12,13 
MR1	presents	riboflavin	metabolites	synthesized	by	microbes	to	the	
TCR	of	the	MAIT-	cell.14	Viruses	do	not	metabolize	riboflavin	and	were	
shown	 to	 activate	MAIT-	cells	 in	 a	TCR-	independent	 fashion	depen-
dent	on	IL-	18	in	synergy	with	IL-	12,	IL-	15	and/or	type	I	interferon.8,11
Recently,	many	studies	demonstrated	that	MAIT-	cells	are	depleted	
from	blood	of	HIV-	infected	individuals,	and	express	exhaustion	mark-
ers.	Interestingly,	their	numbers	are	not	fully	restored	despite	effective	
cART.	Recently,	we	and	others	demonstrated	similar	findings	for	HCV-	
infected	 patients.8,15,16	 In	 these	 patients,	MAIT-	cells	were	 depleted	
from	 peripheral	 blood,	 and	 successful	 interferon-	free	 therapy	 was	
unable	 to	 restore	 their	 numbers	 and	 function,15,16	while	 restoration	
was	observed	for	impaired	CD8+	T	cells	and	NK-	cells.16-18	The	mecha-
nisms	underlying	MAIT-	cell	depletion	from	blood	during	HIV	and	HCV	
infection	remain	unclear.	Activation-	induced	cell	death	and	accumula-
tion	at	the	site	of	infection	and	inflammation,	such	as	the	liver	in	HCV	
infection,	may	explain	this	phenomenon.8,15,16,19	However,	at	least	for	
HIV	infection	this	hypothesis	seems	unlikely,	as	MAIT-	cells	were	sys-
temically	depleted	 in	simian	 immunodeficiency	virus-	infected	rhesus	
macaques,	a	model	often	used	to	investigate	HIV.20
Enhanced	fibrosis	development	in	HCV/HIV	co-	infection	has	been	
associated	with	 enhanced	 translocation	 of	 gut	microbial	 products	 in	
HIV,	which	drives	 continuous	 immune	activation.3,4	 Since	MAIT-	cells	
are	abundantly	present	in	human	liver	perfusates,21,22	depleted	during	
HIV	and	HCV	infection,	and	are	important	in	antimicrobial	immunity,	we	
hypothesized	that	MAIT-	cells	play	a	role	in	HCV-	related	liver	pathology	
and	especially	in	HCV/HIV	co-	infection.	To	examine	this	hypothesis,	we	
compared	peripheral	blood	vs	liver	residing	MAIT-	cell	frequencies,	im-
mune	phenotype	and	function	in	individuals	with	HCV	mono-	infections	
and	HCV/HIV	co-	infections	with	different	fibrosis	scores.
2  | MATERIALS AND METHODS
2.1 | Inclusion of patients and healthy subjects
Ethical	approval	for	this	study	was	obtained	from	the	Ethical	Review	
Boards	of	Erasmus	MC,	University	MC	Utrecht,	 and	University	MC	
Hamburg.	Participants	signed	informed	consent	and	patient	data	were	
anonymized.	 At	 the	 outpatient	 clinics,	 heparinized	 blood	 was	 col-
lected	from	patients	with	chronic	HCV	infection	(n	=	20),	chronic	HCV	
patients	with	cART-	suppressed	HIV	(HCV/HIV;	n	=	22),	patients	with	
Key points
•	 Hypothesis:	MAIT-cells	are	important	innate	T	cells	with	
antimicrobial	 and	 immunoregulatory	 activity	 that	 may	
play	a	role	in	HCV	and	HIV/HCV-related	liver	pathology.
•	 This	study:	MAIT-cells	are	severely	depleted	in	HIV/HCV	
patients	with	advanced	fibrosis.
•	 This	 study:	 MAIT-cells	 seem	 dysfunctional	 in	 blood	 of	
HCV	mono-infected	patients.
•	 This	study:	There	is	no	evidence	for	MAIT-cell	accumula-
tion	in	the	liver.
TABLE  1 Characteristics	of	healthy	controls	and	patients
Healthy
HCV 
F0- F1
HCV 
F3- F4 HIV
HCV/HIV 
F0- F1
HCV/HIV 
F3- F4
N 9 9 11 9 13 9
Gender	(%	male) 100% 100% 100% 100% 100% 100%
Age	(y) 40	(28-	50) 54	(45-	68) 51	(47-	57) 47	(31-	58) 48	(23-	71) 52	(50-	67)
ALT	(U/L) 57	(24-	95) 100	(38-	211) 25	(21-	31) 56	(20-	270) 67	(32-	132)
HCV	RNA	(IU/mL) 4.38	×	106 2.90	×	106 2.15	×	106 1.30	×	106
HCV	genotype	1/2/3/4 8/0/0/1 8/1/1/1 9/1/0/3 7/0/2/0
HIV	load	(geg/mL) All	<20 All	<20 All	<20
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cART-	suppressed	HIV	mono-	infection	(n	=	9).	In	addition,	blood	was	
collected	from	healthy	volunteers	working	at	Erasmus	MC	after	writ-
ten	informed	consent	(n	=	9).	The	patient	characteristics	are	presented	
in	Table	1.	Fine	needle	aspiration	biopsies	(FNAB)	were	collected	from	
patients	 with	 chronic	 HCV	 infection	 (n	=	10)	 and	 cART-	suppressed	
HCV/HIV	 infection	 (n	=	8).	The	characteristics	of	 these	patients	are	
presented	in	Table	2.
Liver	fibrosis	was	scored	using	ultrasound	and	 liver	elastography	
(Fibroscan®).	Liver	pathology	was	either	categorized	as	low,	meaning	
absent	to	mild	liver	fibrosis	(Metavir-	score	F0-	F1)	or	high,	meaning	se-
vere	liver	fibrosis	to	cirrhosis	(Metavir-	score	F3-	F4).	Only	males	were	
included,	 aged	 between	20	 to	 71	years	 old,	with	 undetectable	viral	
HIV	RNA	 levels,	 compliant	use	of	 cART	and	no	 further	 comorbidity	
like:	autoimmune	disease,	cancer,	co-	infection	with	non-	related	viral	
or	sexual	transmitted	infections.
2.2 | Acquisition of peripheral blood mononuclear 
cells and liver cells
FNAB	 for	 intrahepatic	 cells	 were	 performed	 as	 described	 before.23,24 
Peripheral	 blood	mononuclear	 cells	 (PBMC)	were	 isolated	 using	 ficoll	
separation	(Ficoll-	Paque™	plus,	GE	Healthcare	Bio-Sciences	AB,	Uppsala,	
Sweden).	Approximately,	15	million	blood	 lymphocytes	were	used	 for	
analyses	and	the	remainder	was	frozen	at	−150°C.
2.3 | Phenotyping by flowcytometry
PBMC	were	thawed,	and	washed	with	RPMI	1640	supplemented	with	
10%	fetal	calf	serum	(Lonza,	Walkersville,	MD,	USA).	For	flowcytometry,	
500	000	viable	PBMC	were	stained	with	anti-	CD8-	FITC(RPA-	T8);	anti-	
CD3-	Amcyan(SK7);	anti-	CD161-	eFluor450(HP-	3G10);	Anti-	TCR	Vα7.2-	
PE(3C10);	 anti-	CD56-	APC(N901);	 anti-	CD56-	APC-	eFluor780(CMSSB);	
anti-	CD38-	PerCp-	eFluor710(HB7);	or	anti-	HLA-	DR-	PerCP-	Cyanine5.5 
(LN3)	for	20	minutes	at	4°C.	Marker	expression	was	detected	by	flowcy-
tometry	(MACSQuant	Analyser	10	[Miltenyi	Biotec,	Cologne,	Belgium]).	
MAIT-	cells	were	defined	as	CD3+CD161+Vα7.2+	 cells	within	 the	 lym-
phocyte	gate	and	NK-	cells	were	defined	as	CD3−CD56+	cells	within	the	
lymphocyte	gate.
Liver	aspirates	and	paired	blood	were	stained	with	anti-	CD3-	Alexa-	
Fluor700(OKT-	3);	anti-	CD56-	APC-	eFluor780(CMSSB);	anti-	CD45-	PE-	
eFluor610(HI30);	anti-	CD235a-	FITC(HIR2)	or	anti-	CD4-	FITC(13B8.2);	
anti-	CD3-	eVolve605(RPA-	T8);	 anti-	TCR	 Vα7.2-	PE(3C10);	 anti-	
CD161-	eFluor450(HP-	3G10);	and	Live/Dead	Aqua	(Life	Technologies,	
Carlsbad,	CA,	USA).	Cells	were	analysed	using	a	FACS	ARIA	cell	sorter	
(BD-	Biosciences),	San	Jose,	CA,	USA	and	MACSQuant	Analyser	10.	All	
antibodies	were	 purchased	 from	 eBioscience	 (San	Diego,	 CA,	 USA),	
Beckman	(Brae,	CA,	USA)	or	Biolegend	(London,	UK).
2.4 | Analysis of intracellular cytokines by 
flowcytometry
The	 percentages	 of	 cells	 producing	 IFN-	γ	 and	 granzyme-	B	 were	
measured	by	flowcytometry	using	various	stimuli.	For	each	condition,	
duplicate	wells	with	250	000	PBMCs	were	cultured	in	a	96	wells	plate.	
Various	combinations	of	the	following	stimuli	were	used	as	indicated;	
IL-	12	(0.25	ng/mL,	Miltenyi),	IL-	18	(50	ng/mL,	MBL),	CD28	monoclo-
nal	antibody	(2	ug/mL,	eBiosciences),	R848	(1	μg/mL,	Invivogen,	San	
Diego,	CA,	USA),	Escherichia coli	ATCC	25922	(fixed	for	20	minutes	in	
2%	formaldehyde,	25	bacteria	per	lymphocyte),	and	E. coli	K12	(fixed	
for	5	minutes	in	1%	formaldehyde,	25	bacteria	per	lymphocyte).	For	all	
conditions,	cells	were	incubated	for	a	total	of	24	hours	at	37°C	at	5%	
CO2.	Brefeldin	A	(10	μg/mL,	Sigma)	was	added	after	6	or	21	hours	of	
culture	as	indicated	in	the	figure	legend.	Cells	were	stained	with	anti-	
CD3-	PerCp-	Cy5.5(UCHT1),	 anti-	CD8-	APC-	H7(SK3),	 anti-	CD161-	
eFluor450(HP-	3G10),	 anti-	TCR	 Vα7.2-	PE(3C10),	 CD56-	APC(N901,	
Beckman)	 and	 Live/dead	 Aqua,	 fixed,	 permeabilized	 and	 stained	
with	 anti-	IFN-	γ-	PE-	Cy7(4S.B3)	 and	 anti-	granzyme-	B-	FITC(GB11).	
Cytokine-	producing	 cells	 were	 detected	 by	 flowcytometry	 using	 a	
MACSQuant	Analyser	10.	Gating	of	cells	was	set	on	internal	controls	
with	low	or	absent	expression	on	lineage	negative	cells.	Only	samples	
with	more	than	80	MAIT-	cell	events	were	included	for	expression	of	
surface	markers,	IFN-	γ	and	granzyme-	B.
2.5 | Statistics
Flowcytometric	 data	 were	 analysed	 using	 Flow JoTM	 (TreesTar,	
windows 7	 version	 10.0.8).	 Statistical 	 comparison	 was	 performed	
using	 the	Kruskal-	Wallis	 and	Mann-	Whitney	 test	 for	 unpaired	non-	
parametric	analyses.	A	P	value	≤	.05	was	considered	significant.
3  | RESULTS
3.1 | MAIT- cells are severely depleted in blood of 
HCV, HIV and HCV/HIV patients
It	has	been	reported	that	MAIT-	cells	are	depleted	in	blood	of	HIV	and	
HCV	patients.8,11,15,16,19,25-30	We	confirmed	these	findings	by	perform-
ing	 flowcytometry	 on	 CD3+CD161+TCR	 Vα7.2+MAIT-	cells	 in	 blood	
of	20	chronic	HCV	patients,	nine	HIV	patients	on	cART,	and	22	HIV	
patients	on	cART	co-	infected	with	HCV,	as	compared	to	nine	healthy	
individuals	(Table	1,	Figure	1A).	Only	patients	without	or	with	only	mild	
liver	fibrosis	(F0-	F1)	were	included	for	comparison.	The	frequencies	of	
circulating	MAIT-	cells,	but	not	CD56+CD3−	NK-	cells,	were	significantly	
lower	 in	HCV-	,	HIV-	and	HCV/HIV-	infected	patients	as	compared	 to	
healthy	individuals	(Figure	1B),	whereas	MAIT-	cells	obtained	from	these	
virus-	infected	patients	were	more	activated	as	demonstrated	by	higher	
frequencies	of	CD38	and	HLA-	DR-	expressing	MAIT-	cells	 (Figure	1C).	
An	increase	in	the	frequencies	of	the	CD161−TCR	Vα7.2+	cell	popula-
tion	was	observed	only	in	HCV/HIV-	infected	patients	(Fig.	S1).
3.2 | Effector functions of blood MAIT- cells are 
preserved in HCV, HIV and HCV/HIV patients with low 
levels of liver disease
MAIT-	cells	 can	be	 triggered	by	 stimuli,	 such	 as	 the	TLR7/8	 agonist	
R848,	 E. coli	 and	 the	 cytokines	 IL-	12/IL-	18	 to	 exert	 their	 effector	
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functions.9,11,22	 MAIT-	cells	 of	 healthy	 individuals	 stimulated	 with	
E. coli	 or	 R848	 alone	 exhibited	 low	 frequencies	 of	 cells	 producing	
IFN-	γ	 or	 the	 cytolytic	 enzyme	 granzyme-	B,	 whereas	 IL-	12/IL-	18	
stimulation	 resulted	 in	 18%	 IFN-	γ+	 and	 7.5%	 granzyme-	B+	 MAIT-	
cells	(Figure	2).	Additional	triggering	of	IL-	12/IL-	18	with	either	R848	
or E. coli	 further	 increased	the	frequencies	of	effector-	MAIT-	cells	 in	
healthy	individuals.	Stronger	IFN-	γ	responses	were	detected	after	al-
teration	of	 the	E. coli	 stimulation	 in	 line	with	 an	optimized	protocol	
recently	published	by	Dias	and	colleagues31: E. coli	strain	K12	instead	
of	ATCC	25922	was	used,	the	E. coli	bacteria	were	fixed	for	5	minutes	
instead	of	20	minutes	in	1%	formaldehyde,	and	brefeldin	A	was	added	
to	 the	culture	after	6	hours	 instead	of	21	hours	of	stimulation.	This	
resulted	 in	robust	 IFN-	γ	production	by	MAIT-	cells	 (see	Figs.	S4	and	
S5).	IFN-	γ	production	by	MAIT-	cells	could	be	further	enhanced	by	the	
addition	of	either	anti-	CD28	or	IL-	12/IL-	18	(see	Figs.	S4	and	S5).
Next,	 we	 studied	 the	 impact	 of	 chronic	 HCV,	 HIV	 and	 chronic	
HCV/HIV	 infection	 on	MAIT	 effector	 functions	 in	 patients	without	
or	with	only	mild	liver	fibrosis	(F0-	F1).	To	rule	out	the	impact	of	liver	
fibrosis	on	these	effector	functions,	a	subset	of	F0-	F1	patients	from	
Figure	1	were	studied,	and	patients	with	severe	fibrosis	(F3-	F4)	were	
not	included	in	this	comparison.	Albeit	that	MAIT-	cells	were	severely	
depleted	in	blood	of	HCV,	HIV	and	HCV/HIV	patients	(Figure	1B),	we	
observed	no	reduction	in	MAIT-	cell	functions	as	compared	to	healthy	
individuals.	HIV	mono-	infected	patients	 generally	 showed	 increased	
IFN-	γ	 and	 granzyme-	B	 production	 and	 upon	 E. coli	 in	 addition	 to	
IL-	12/IL-	18	 stimulation,	 we	 even	 observed	 a	 65%	 increase	 in	 IFN-	
γ-	producing	MAIT-	cells	 (Figure	2A).	 It	 is	 important	 to	 note	 that	 the	
frequencies	of	monocytes,	which	are	 triggered	by	E. coli	or	R848	 to	
secrete	MAIT-	cell-	activating	cytokines,	were	comparable	in	all	experi-
mental	groups	(mean	13.5%	of	viable	PBMC,	range	10.5%-	15.1%).
Moreover,	the	frequency	of	IFN-	γ-	producing	blood	NK-	cells	from	
the	same	patients	was	also	comparable	between	the	four	experimen-
tal	groups,	except	from	HIV	patients	who	showed	reduced	frequen-
cies	of	cytokine-	producing	NK-	cells	upon	certain	stimuli.	The	majority	
of	 blood	NK-	cells	 spontaneously	 expressed	 granzyme-	B,	which	was	
increased	 to	 almost	 all	 blood	NK-	cells	 upon	 stimulation	with	 IL-	12/
IL-	18,	E. coli	or	R848	(Fig.	S2	and	data	not	shown).
Overall,	 these	 findings	 show	 that	 despite	 lower	 frequencies	 of	
MAIT-	cells	 in	blood,	 the	 function	of	MAIT-	cells	obtained	 from	HCV	
or	HCV/HIV	patients	without	or	with	minimal	fibrosis	(F0-	F1)	is	main-
tained	 as	 compared	 to	 healthy	 individuals,	 or	 even	 enhanced	 upon	
stimulation	with	E. coli	and	IL-	12/IL-	18	in	HIV	patients.
3.3 | MAIT- cell frequencies are more depleted in 
blood of HCV/HIV co- infected patients with severe 
fibrosis and cirrhosis vs no to mild fibrosis
Next,	we	determined	the	peripheral	blood	MAIT-	cell	frequencies	in	
individuals	with	HCV	mono-	infections	 and	HCV/HIV	 co-	infections	
with	different	fibrosis	scores.	To	examine	this,	we	compared	patients	
with	severe	liver	fibrosis	to	cirrhosis	(F3-	F4)	vs	patients	without	or	
with	only	mild	fibrosis	 (F0-	F1)	that	were	also	 included	 in	Figures	1	
and	 2.	 As	 shown	 in	 Figure	3A,	 we	 observed	 that	 in	 HCV	 mono-	
infected	patients	the	frequencies	of	MAIT-	cells	in	blood	were	com-
parable	in	patients	with	F0-	F1	vs	F3-	F4.	However,	significant	lower	
MAIT-	cell	frequencies	were	detected	in	blood	of	HCV/HIV	patients	
with	F3-	F4	as	compared	to	F0-	F1	(P	=	.024;	median	0.350	and	0.880	
respectively).	 Importantly,	 the	 frequencies	 of	 CD3+CD161−TCR	
Vα7.2+	cells	were	not	significantly	different	 in	patients	with	F3-	F4	
as	 compared	 to	 F0-	F1,	 and	 loss	 of	 CD161	 could	 not	 explain	 the	
decrease	 in	 CD3+CD161+TCR	Vα7.2+MAIT-	cells	 (data	 not	 shown).	
In	addition,	 frequencies	of	NK-	cells	were	not	modulated	as	a	con-
sequence	 of	 differences	 in	 fibrosis	 scores	 in	 either	 patient	 group	
(Figure	3A).
The	 frequency	 of	 CD38+	 and	 HLA-	DR+	MAIT-	cells	 in	 HCV	 and	
HCV/HIV	co-	infected	patients	was	 significantly	 increased	compared	
to	 those	 of	 healthy	 individuals	 (Figure	1C),	 but	when	 stratifying	 for	
liver	fibrosis	we	observed	no	significant	modulation	of	the	frequency	
of	 CD38+	 or	 HLA-	DR+	MAIT-	cells	 in	 patients	with	 F0-	F1	 vs	 F3-	F4	
(Figure	3B).	Also	for	NK-	cells,	no	significant	differences	were	observed	
when	comparing	the	patients	with	different	fibrosis	scores.
3.4 | Reduced function of MAIT- cells in blood of 
HCV mono- infected patients with severe fibrosis and 
cirrhosis vs no to mild fibrosis
To	 determine	 whether	 fibrosis	 scores	 affected	 the	 functionality	 of	
MAIT-	cells	 in	 these	 patients,	 PBMC	were	 stimulated	 as	 before.	 As	
HCV 
F0- F1
HCV 
F3- F4
HCV/HIV 
F0- F1
HCV/HIV 
F3- F4
N 6 4 5 3
Gender	(%	male) 100% 100% 100% 100%
Age	(y) 58	(53-	62) 51	(45-	58) 58	(52-	62) 51	(45-	58)
ALT	(U/L) 57	(24-	95) 103	(60-	147) 49	(20-	79) 61	(45-	81)
HCV	RNA	(IU/mL) 2.72	×	106 5.4	×	106 1.28	×	106 1.24	×	106
HCV	genotype	
1/2/3/4
6/0/0/0 2/0/2/0 4/0/0/1 3/0/0/0
HIV	load	(geq/mL) All	<20 All	<20
Fibrosis	F0/1/2/3/4 3/3/0/0/0 0/0/0/3/1 2/3/0/0/0 0/0/0/1/2
TABLE  2 Characteristics	of	patients	
who	donated	fine	needle	aspirates	of	the	
liver
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F IGURE  1 Mucosal-	associated	invariant	T	(MAIT)-	cells	are	severely	depleted	in	blood	of	HCV,	HIV	and	HCV/HIV	patients.	(A)	Viable	MAIT-	
cells	were	identified	using	flowcytometry	as	lymphocytes	expressing	CD3,	CD161	and	TCR	Vα7.2.	(B)	MAIT-	cell	and	NK-	cell	frequencies	and	 
(C)	the	frequency	of	CD38+	or	HLA-	DR+	MAIT-	cells	or	NK-	cells	were	determined	in	blood	of	healthy	individuals,	HCV,	HIV	and	HCV/HIV	
patients,	all	with	no	or	low	levels	of	fibrosis	(F0-	F1)
MAIT cells NK cells
%
L
y
m
p
h
o
c
y
te
s
0
1 0
2 0
3 0
4 0
%
o
f
to
ta
l
T
c
e
ll
s
0
5
1 0
1 5
P = < 0 0 0 0 1
P = .0 0 0 1
P = .0 0 0 6
Healthy 
control
HCV HCV/HIVHIV
% CD38+
cells
%
o
f
N
K
c
e
ll
s
0
2 0
4 0
6 0
8 0
1 0 0
%
o
f
M
A
IT
c
e
ll
s
0
2 0
4 0
6 0
8 0
P =.0 1 4 2
P =.0 0 0 5
P = .0 0 4 6
Healthy 
control
HCV HCV/HIVHIV
Live/dead
(A)
(B)
(C)
FSC
CD161
TCR Vα7.2
CD56
CD3
SSC
FSC
%
o
f
N
K
ce
ll
s
0
2 0
4 0
6 0
8 0
1 0 0
Healthy 
control
HCV HCV/HIVHIVHealthy 
control
HCV HCV/HIVHIV
% HLA-DR+
cells
%
o
f
M
A
IT
c
e
ll
s
0
2 0
4 0
6 0
8 0
P= .0 3 9 9
P= .0 1 0 6
P= .0 0 4 2
SSC
CD38
HLA-DR
SSC
Healthy 
control
HCV HCV/HIVHIV
Healthy 
control
HCV HCV/HIVHIV
6  |     BEUDEKER Et al.
shown	in	Figure	4,	we	observed	in	HCV	mono-	infected	patients	a	sig-
nificant	reduction	of	the	frequencies	of	IFN-	γ+	MAIT-	cells	in	blood	of	
patients	with	severe	liver	fibrosis	to	cirrhosis	(F3-	F4)	vs	patients	with-
out	or	with	only	mild	fibrosis	(F0-	F1)	upon	stimulation	with	IL-	12/IL-	
18	alone,	or	in	combination	with	E. coli	or	R848.	Using	the	optimized	
protocol	 for	E. coli	 stimulation	 of	MAIT-	cells,31	we	 confirmed	 these	
findings.	Further,	we	observed	the	same	trend	for	E. coli	stimulation	
alone and E. coli	in	combination	with	anti-	CD28,	albeit	that	this	effect	
did	not	reach	significance	(Fig.	S5).	Moreover,	upon	stimulation	with	
IL-	12/IL-	18	alone,	a	significant	reduction	of	the	frequencies	of	gran-
zyme-	B+	MAIT-	cells	was	observed	in	the	HCV	mono-	infected	patients	
with	F3-	F4	vs	F0-	F1	(P	=	.0229).	In	contrast,	patients	with	HCV/HIV	
co-	infections	exhibited	comparable	frequencies	of	IFN-	γ+	MAIT-	cells	
and	granzyme-	B+	MAIT-	cells	upon	stimulation.	These	alterations	were	
observed	 for	blood	MAIT-	cells,	but	not	 for	NK-	cells	 from	 the	 same	
patients	(Fig.	S3).
In	summary,	our	findings	suggest	that	MAIT-	cell	effector	functions	
are	 reduced	 in	HCV	mono-	infected	patients	with	 severe	 liver	 fibro-
sis	and	cirrhosis	as	reflected	by	reduced	frequencies	of	granzyme-	B+ 
MAIT-	cells	upon	stimulation	with	IL-	12/IL-	18.
3.5 | Ex vivo intrahepatic MAIT- cells do not differ in 
frequency in HCV mono- infected vs HCV/HIV patients
A	possible	explanation	for	the	reduced	numbers	of	circulating	MAIT-	
cells	 in	HCV	mono-	c	evaluation	of	the	aspirates	demonstrated	that	
the	frequencies	of	MAIT-	cells	in	the	liver	of	HCV	and	HCV/HIV	pa-
tients	without	or	with	only	mild	 fibrosis	 (F0-	F1)	were	 relatively	 low	
(HCV	liver:	median	1.11%;	HCV/HIV	liver:	median	1.08%	of	the	total	
intrahepatic	T	cells),	but	higher	 than	 in	blood.	 Importantly,	 the	per-
centage	of	intrahepatic	CD161−TCR	Vα7.2+	cells	was	comparable	in	
all	patient	groups	(data	not	shown).	Also,	as	shown	in	Figure	5B,	no	
F IGURE  2 Effector	functions	of	blood	mucosal-	associated	invariant	T	(MAIT)-	cells	are	preserved	in	HCV,	HIV	and	HCV/HIV	patients	with	no	
or	low	levels	of	liver	fibrosis.	PBMC	from	subjects	with	no	or	low	levels	of	fibrosis	(F0-	F1)	were	stimulated	for	24	hours	with	medium,	Escherichia 
coli	ATCC	25922,	and	R848,	alone	or	in	combination	with	IL-	12/IL-	18,	with	brefeldin	A	being	added	after	21	hours.	Intracellular	staining	for	
IFN-	γ	(A)	and	granzyme-	B	(B)	was	assessed	for	MAIT-	cells
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increased	MAIT-	cell	frequencies	were	observed	in	the	liver	of	the	pa-
tients	with	severe	fibrosis	or	cirrhosis	as	compared	to	patients	without	
fibrosis.	These	findings	suggest	that	the	more	pronounced	depletion	
of	MAIT-	cells	 in	 blood	 of	 HCV/HIV	 co-	infected	 patients	 with	 high	
fibrosis	scores,	as	presented	 in	Figure	3A,	 is	not	reflected	by	higher	
frequencies	in	the	liver	of	this	population	in	the	same	patient.
4  | DISCUSSION
In	 line	with	an	 increasing	number	of	studies,	we	confirmed	that	the	
frequency	of	MAIT-	cells	in	blood	of	HCV-	and	HIV	mono-	infected	pa-
tients	is	reduced,	while	these	cells	are	more	activated	as	evidenced	by	
higher	expression	of	CD38	and	HLA-	DR8,15,16,19,25-30	We	now	show,	
for	 the	 first	 time,	 that	MAIT-	cells	 are	 also	 depleted	 and	more	 acti-
vated	in	blood	of	patients	chronically	co-	infected	with	HCV	and	HIV	
as	compared	to	healthy	 individuals,	without	evidence	for	accumula-
tion	in	the	liver	as	shown	using	aspirate	biopsies.	In	line	with	literature,	
we	observed	that	MAIT-	cells	retain	their	cytokine-	producing	capac-
ity	 in	patients	 infected	with	HIV29,30	as	well	as	HCV16	as	compared	
to	 healthy	 individuals.	 Further	 supported	 by	 the	 findings	 that	 in	 all	
patient	 groups	 enhanced	 CD38	 and	 HLA-	DR	 expression	 was	 ob-
served,	 it	 is	clear	that	blood	MAIT-	cells	are	fully	 functional	 in	these	
patients.	Interestingly,	in	HIV	mono-	infected	patients,	but	not	in	HCV	
mono-	infected	or	co-	infected	patients,	we	even	observed	 increased	
frequencies	 of	 IFN-	γ-	 and	 granzyme-	B-	producing	 MAIT-	cells	 with	
certain	stimuli,	which	further	supports	that	their	 functionality	 is	not	
impaired.
Since	 MAIT-	cells	 are	 abundantly	 present	 in	 human	 liver	 perfu-
sates21,22	and	important	in	antimicrobial	 immunity,	we	examined	the	
possible	 association	 between	 the	 frequency	 and	 function	 of	MAIT-	
cells	and	the	degree	of	HCV-	related	liver	pathology.	Interestingly,	we	
F IGURE  3 Mucosal-	associated	invariant	T	(MAIT)-	cell	frequencies	are	more	depleted	in	blood	of	HCV/HIV	co-	infected	patients	with	severe	
fibrosis	vs	low	fibrosis.	(A).	The	frequencies	of	MAIT-	cells	and	NK-	cells,	and	(B)	the	frequencies	of	CD38+	or	HLA-	DR+	MAIT-	cells	or	NK-	cells	
were	determined	in	blood	of	HCV	mono-	infected	and	HCV/HIV	co-	infected	patients	with	F0-	F1	or	F3-	F4	fibrosis	score
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observed	that	HCV/HIV	co-	infected	patients	with	severe	 liver	fibro-
sis	or	cirrhosis	 (F3-	F4)	had	lower	frequencies	of	MAIT-	cells	 in	blood	
as	compared	to	patients	without	fibrosis	 (F0-	F1).	This	was	observed	
for	co-	infected	patient,	but	not	for	HCV	mono-	infected	patients.	The	
lack	of	correlation	of	MAIT-	cell	frequencies	and	fibrosis	scores	in	HCV	
mono-	infected	patients	as	opposed	to	co-	infected	patients	confirms	
our	 earlier	 study	 in	 an	 independent	 cohort.16	Moreover,	MAIT-	cells	
from	HCV/HIV	co-	infected	patients	with	severe	fibrosis	are	not	more	
activated,	 and	 do	 not	 produce	 more	 IFN-	γ	 than	 their	 counterpart	
from	co-	infected	patients	without	fibrosis.	Interestingly,	in	contrast	to	
HCV/HIV	co-	infected	patients,	MAIT-	cells	obtained	from	HCV	mono-	
infected	patients	with	severe	fibrosis	are	not	more	depleted,	but	show	
lower	frequencies	of	IFN-	γ-	producing	cells	as	well	as	a	clear	trend	to-
wards	reduced	frequencies	of	granzyme-	B+	cells	as	compared	to	their	
F IGURE  4 Mucosal-	associated	invariant	T	(MAIT)-	cell	function	is	reduced	in	blood	of	HCV	mono-	infected	patients	with	severe	fibrosis	vs	
low	fibrosis.	PBMC	of	HCV	mono-	infected	and	HCV/HIV	co-	infected	patients	with	F0-	F1	or	F3-	F4	fibrosis	score	were	stimulated	with	medium,	
Escherichia coli	ATCC	25922,	and	R848,	alone	or	in	combination	with	IL-	12/IL-	18,	with	brefeldin	A	being	added	after	21	hours.	Intracellular	
staining	for	IFN-	γ	(A)	and	granzyme-	B	(B)	was	assessed	for	MAIT-	cells
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counterparts	with	low	fibrosis	scores.	Both	in	F3-	F4	patients	with	HCV	
mono-	infections	 as	well	 as	 in	 patients	with	HCV/HIV	 co-	infections,	
MAIT-	cells	 seem	 impaired.	However,	 in	HCV/HIV	co-	infections	only	
MAIT-	cell	numbers	are	decreased,	whereas	 in	HCV	mono-	infections	
only	MAIT-	cell	functionality	is	hampered,	reflected	by	reduced	IFN-	γ 
production	and	granzyme-	B	expression.
Likely,	 similar	 processes	may	 be	 responsible	 for	 these	 divergent	
findings.	MAIT-	cell	depletion	in	HCV/HIV	co-	infected	patients	may	be	
the	consequence	of	the	interplay	between	inflammation	caused	by	en-
hanced	microbial	translocation	from	the	gut	via	the	portal	vein	to	the	
liver	and	sustained	immune	activation	as	a	consequence	of	HIV	infec-
tion.	HIV	infection	possibly	further	reduces	the	number	of	MAIT-	cells	
in	advanced	fibrosis	patients.	On	the	other	hand,	we	show	in	Figure	2	
that	HIV	induces	higher	IFN-	γ	production	and	granzyme-	B	expression	
in	MAIT-	cells	which	may	explain	why	HCV/HIV	co-	infected	patients	
with	advanced	fibrosis	show	similar	MAIT-	cell	functions	as	in	patients	
without	 or	with	 only	mild	 fibrosis.	This	 balance	 is	 likely	 different	 in	
HCV	mono-	infected	patients,	and	possibly	leakage	of	microbial	prod-
ucts	from	the	intestine	only	occurs	in	these	patients	after	the	liver	has	
become	severely	fibrotic.
To	rule	out	that	our	experimental	set-	up	was	responsible	for	our	
findings,	we	repeated	our	MAIT	IFN-	γ	production	experiments	on	iden-
tical	samples	using	an	optimized	protocol	recently	published	by	Dias	
and	 colleagues.31	Based	on	 availability	of	 samples,	we	 repeated	 the	
experiments	on	samples	of	46	subjects	including	six	healthy	controls,	
all	nine	HIV	mono-	infected	and	all	20	HCV	mono-	infected	patients.	
Because	of	limited	availability	of	archived	PBMC	samples	of	some	pa-
tients,	 only	 seven	HCV/HIV	 co-	infected	patients	without	 significant	
fibrosis	(F0-	F1)	and	four	with	severe	fibrosis	to	cirrhosis	(F3-	F4)	could	
be	included.	Using	a	different	E. coli	strain,	fixation	method	and	kinet-
ics,	we	confirmed	our	previous	findings	that	the	frequencies	of	IFN-	γ+ 
MAIT-	cells	in	blood	of	HCV	mono-	infected	patients	with	severe	liver	
fibrosis	to	cirrhosis	(F3-	F4)	vs	patients	without	or	with	only	mild	fibro-
sis	(F0-	F1)	were	significantly	reduced	after	E. coli/IL-	12/IL-	18	or	IL-	12/
IL-	18	stimulation.	Further,	we	observed	the	same	trend	for	E. coli	stim-
ulation	alone	and	E. coli	in	combination	with	anti-	CD28,	albeit	that	this	
effect	did	not	reach	significance	(Fig.	S5).
A	 suggested	 theory	 for	 the	 observed	MAIT-	cell	 depletion	 from	
blood	is	that	the	MAIT-	cells	of	HCV/HIV	co-	infected	patients	migrate	
to	the	liver	in	response	to	the	chronic	infection.10,19,26,29,32	However,	
we	observed	no	indications	for	enhanced	migration	of	MAIT-	cells	to	
the	 liver	 in	co-	infected	patients	with	F3-	F4	as	compared	to	patients	
with	 F0-	F1.	 In	 fact,	 although	 the	 number	 of	 liver	 aspirate	 biopsies	
that	could	be	examined	is	small,	it	even	appears	that	in	HCV/HIV	co-	
infected	patients	with	severe	fibrosis	the	frequency	is	lower,	making	it	
unlikely	that	enhanced	MAIT-	cell	migration	to	the	liver	is	occurring	in	
these	patients.	Importantly,	the	percentage	of	MAIT-	cells	as	a	propor-
tion	of	T	cells	does	not	necessarily	reflect	absolute	MAIT	frequencies.	
However,	 the	number	of	 lymphocytes	we	purified	from	F0-	F1	 livers	
was	similar	or	slightly	higher	than	the	number	purified	from	F3-	F4	liv-
ers.	Therefore,	it	is	unlikely	that	in	HCV/HIV	co-	infected	patients	with	
advanced	fibrosis,	enhanced	intrahepatic	cellular	infiltration	accompa-
nied	by	a	concurrent	migration	of	MAIT-	cells	to	these	livers	explains	
our	finding	that	MAIT-	cells	are	depleted	more	profoundly	in	blood	of	
patients	with	high	fibrosis	scores.	However,	it	should	be	noted	that	the	
frequencies	of	MAIT-	cells	in	the	livers	of	patients	with	HCV	and	HCV/
HIV	obtained	by	fine	needle	aspiration	are	much	lower	than	the	fre-
quencies	reported	by	other	studies	performed	using	 liver	perfusates	
F IGURE  5 The	frequencies	of	mucosal-	associated	invariant	T	(MAIT)-	cells	are	higher	in	liver	than	blood	in	HCV	mono-	infected	and	HCV/HIV	
co-	infected	individuals.	(A)	Viable	MAIT-	cells	were	identified	in	liver	aspirates	using	flowcytometry	as	viable	CD45+	cells,	lacking	CD235a	and	
expressing	CD3,	CD161	and	TCR	Vα7.2.	(B)	The	frequencies	of	MAIT-	cells	within	the	CD3+	T-	cell	compartment	is	higher	in	liver	than	blood,	but	
overall	not	different	between	individuals	with	F0-	F1	vs	F3-	F4	scores	in	HCV	and	HCV/HIV	patients
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of	healthy	individuals.21,22	It	is	important	to	examine	in	future	studies	
whether	 patient	 cohorts	 and/or	methodological	 factors	 account	 for	
these	differences	in	frequencies.	More	studies	are	also	needed	to	in-
vestigate	whether	MAIT-	cells	migrate	to	the	hepatic	lymph	nodes	of	
HCV	mono-	and	HCV/HIV	co-	infected	patients.	Also,	information	on	
the	distribution	of	MAIT-	cells	 in	healthy	 individuals	 and	HIV	mono-	
infected	patients	is	needed.	Notwithstanding	the	profound	relevance,	
acquisition	of	these	data	 is	challenging	because	of	difficult	 inclusion	
of	 patients	 and	 healthy	 volunteers,	 and	 partly	 because	 of	 ethical	
constraints.
Another	 suggested	 explanation	 for	 the	 depletion	 of	
CD3+CD161+TCR	Vα7.2+MAIT-	cells	is	downregulation	of	CD161.28,33 
Indeed,	we	observed	an	increase	in	CD3+CD161−TCR	Vα7.2+	cells	in	
HCV/HIV-	infected	 patients	 (Fig.	 S1).	 However,	 this	 did	 not	 explain	
the	lower	proportion	of	MAIT-	cells	found	in	our	HCV/HIV	co-	infected	
patients	with	advanced	fibrosis	(F3-	F4)	as	opposed	to	patients	with-
out	or	with	only	mild	fibrosis	(F0-	F1),	and	the	percentage	of	intrahe-
patic	CD161−TCR	Vα7.2+	cells	was	comparable	in	all	patient	groups.	
Moreover,	there	is	continuous	debate	whether	these	CD3+TCR	Vα7.2+ 
cells	lacking	CD161	expression	are	truly	MAIT-	cells.	Important	in	this	
is	that	MAIT-	cells	activated	via	their	T-	cell	receptor	by	vitamin	B	me-
tabolites	bound	by	MR1,	are	almost	absent	among	CD3+CD161−TCR	
Vα7.2+	 cells	 in	 healthy	 individuals,34	 and	 in	 HIV-	infected	 patients,	
MR1	tetramers	did	not	bind	to	CD3+CD161−TCR	Vα7.2+	cells.29
At	 present,	 it	 is	 unknown	 if	 the	 dysfunctional	 blood	MAIT-	cells	
in	 HCV	mono-	infected	 patients	 and	 reduced	MAIT-	cell	 numbers	 in	
blood	of	HCV/HIV	co-	infected	 individuals	are	the	cause	or	the	con-
sequence	of	the	more	severe	liver	fibrosis.	Low	MAIT-	cell	frequencies	
as	 compared	 to	 healthy	 individuals	 might	 predispose	 for	 fibrosis	 in	
HCV	mono-	infected	and	this	situation	could	be	accelerated	in	HCV/
HIV	co-	infected	individuals	with	high	fibrosis	scores.	A	dysfunctional	
MAIT-	cell	compartment	likely	impacts	the	antimicrobial	activity,	which	
affects	 clearance	of	microbial	 products	 released	 to	 the	 liver	via	 en-
hanced	microbial	translocation.11	Moreover,	IFN-	γ	has	been	described	
to	possess	antifibrotic	activity,	and	consequently	a	reduction	of	IFN-	γ 
levels	in	the	liver	because	of	decreased	levels	of	IFN-	γ	production	or	
lower	numbers	of	IFN-	γ	-	producing	MAIT-	cells	might	also	promote	fi-
brosis	development.	Unfortunately,	because	of	the	small	numbers	of	
intrahepatic	leucocytes	collected	by	aspiration	of	the	liver,	sufficient	
numbers	of	cells	were	available	for	flowcytometry,	but	not	for	addi-
tional	functional	testing	of	intrahepatic	MAIT-	cells.
In	conclusion,	our	findings	demonstrate	that	the	degree	of	impair-
ment	of	the	MAIT-	cell	compartment	 in	blood	of	HCV	and	HCV/HIV	
patients	 is	more	pronounced	 in	 individuals	with	 severe	 liver	 fibrosis	
or	cirrhosis	as	compared	to	those	without	or	with	only	mild	fibrosis.	
Moreover,	evaluation	of	aspirate	biopsies	of	the	liver	provided	no	ev-
idence	 for	enhanced	MAIT-	cell	migration	 to	 the	 liver	during	chronic	
viral	infections	or	advanced	fibrosis.
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